On-demand CE webinar (originally presented live December 8, 2025 at the ASHP 2025 Midyear Clinical Meeting & Exhibition). Available until February 26, 2027.
ACPE Number: 0204-0000-25-414-H01-P
CE Credits: 1.5 contact hours (0.15 CEUs) — Application-based
Fee: Free
Overview
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an immune-mediated, rare disorder causing muscle weakness and sensory disturbance that can lead to severe disability. This activity reviews pathophysiology, incidence/prevalence, burden of disease, guideline-recommended therapies and their limitations, and the most recent clinical evidence on new and emerging therapies including FcRn antagonists. Pharmacists will learn how to optimize therapy, medication monitoring, medication access, patient education, adherence, care coordination, and adjunct care (including vaccinations).
Learning Objectives
- Describe the pathophysiology, prevalence/incidence, burden of illness, and identification of patients with CIDP.
- Evaluate treatment guidelines and conventional therapies for CIDP.
- Analyze evidence of new and emerging treatments for CIDP including mechanism of action, pharmacology, clinical trial safety/efficacy data, and place in therapy.
- Apply evidence-based approaches to individualize patient-centered treatment and counseling to improve safety, adherence, access, and outcomes.
Target Audience
Pharmacists in hospitals, health systems, specialty pharmacies, and ambulatory clinics who care for or are interested in caring for patients with CIDP.
Faculty
- Claire Spahn, PharmD, MS, BCPS — Activity Chair; Clinical Pharmacist, Stanford Health Care, Stanford, California.
- Neelam Goyal, MD — Clinical Professor of Neurology & Neurological Sciences, Division of Neuromuscular Medicine, Stanford University, Palo Alto, California.
More in this Series
Accreditation
ASHP is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education with Commendation.
